-
1
-
-
79952408175
-
Enhancing prostate cancer care through the multidisciplinary clinic approach: A 15-year experience
-
Gomella LG, Lin J, Hoffman-Censits Jet al. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J. Oncol. Pract. 6(6), e5-e10 (2010).
-
(2010)
J. Oncol. Pract
, vol.6
, Issue.6
, pp. e5-e10
-
-
Gomella, L.G.1
Lin, J.2
Hoffman-Censits, J.3
-
2
-
-
84903476624
-
Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases
-
Zustovich F, Fabiani F. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Crit. Rev. Oncol. Hematol. 9(2), 197-209 (2014).
-
(2014)
Crit. Rev. Oncol. Hematol
, vol.9
, Issue.2
, pp. 197-209
-
-
Zustovich, F.1
Fabiani, F.2
-
3
-
-
26444544162
-
Recent developments in nuclear medicine in the management of bone metastases: A review and perspective
-
Damerla V, Packianathan S, Boerner PS, Jani AB, Vijayakumar S, Vijayakumar V. Recent developments in nuclear medicine in the management of bone metastases: a review and perspective. Am. J. Clin. Oncol. 28(5), 513-520 (2005).
-
(2005)
Am. J. Clin. Oncol
, vol.28
, Issue.5
, pp. 513-520
-
-
Damerla, V.1
Packianathan, S.2
Boerner, P.S.3
Jani, A.B.4
Vijayakumar, S.5
Vijayakumar, V.6
-
4
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213-223 (2013).
-
(2013)
N. Engl. J. Med
, vol.369
, Issue.3
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
5
-
-
84891951693
-
Prostate cancer, version 1.2014
-
Mohler JL, Kantoff PW, Armstrong AJ et al. Prostate cancer, version 1.2014. J. Natl Compr. Canc. Netw. 11(12), 1471-1479 (2013).
-
(2013)
J. Natl Compr. Canc. Netw
, vol.11
, Issue.12
, pp. 1471-1479
-
-
Mohler, J.L.1
Kantoff, P.W.2
Armstrong, A.J.3
-
6
-
-
84890531221
-
Radiometabolic treatment of bone-metastasizing cancer: From 186rhenium to 223radium
-
Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. Cancer Biother. Radiopharm. 29(1), 1-11 (2014).
-
(2014)
Cancer Biother. Radiopharm
, vol.29
, Issue.1
, pp. 1-11
-
-
Rubini, G.1
Nicoletti, A.2
Rubini, D.3
Asabella, A.N.4
-
7
-
-
84881294465
-
Recent advances revolutionize treatment of metastatic prostate cancer
-
Madan RA, Arlen PM. Recent advances revolutionize treatment of metastatic prostate cancer. Future Oncol. 9(8), 1133-1144 (2013).
-
(2013)
Future Oncol
, vol.9
, Issue.8
, pp. 1133-1144
-
-
Madan, R.A.1
Arlen, P.M.2
-
8
-
-
84888303650
-
Targeted α-particle therapy of bone metastases in prostate cancer
-
Jadvar H, Quinn DI. Targeted α-particle therapy of bone metastases in prostate cancer. Clin. Nucl. Med. 38(12), 966-971 (2013).
-
(2013)
Clin. Nucl. Med
, vol.38
, Issue.12
, pp. 966-971
-
-
Jadvar, H.1
Quinn, D.I.2
-
9
-
-
84860201679
-
An alpha edge?
-
Silberstein EB. An alpha edge? Oncology 26(4), 345-348 (2012).
-
(2012)
Oncology
, vol.26
, Issue.4
, pp. 345-348
-
-
Silberstein, E.B.1
-
10
-
-
0025950294
-
Rhenium-186(sn)hedp for treatment of painful osseous metastases: Results of a double-blind crossover comparison withplacebo rhenium-186(sn)hedp for treatment of painful osseous metastases
-
Maxon HR, Schroder LE, Hertzberg VS et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison withplacebo rhenium-186(Sn)HEDP for treatment of painful osseous metastases. J. Nucl. Med. 32, 1877-1881 (1991).
-
(1991)
J. Nucl. Med
, vol.32
, pp. 1877-1881
-
-
Maxon, H.R.1
Schroder, L.E.2
Hertzberg, V.S.3
-
11
-
-
84921413128
-
-
Quadramet prescribing information. http://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=61e84808-0999-4923-910c-2a480d5f971a&type=pdf&name=61e84808-0999-4923-910c-2a480d5f971a
-
Quadramet Prescribing Information
-
-
-
12
-
-
83455195239
-
Radiopharmaceuticals for painful bone metastases: Perspective from radiation oncology
-
Barnes EA. Radiopharmaceuticals for painful bone metastases: perspective from radiation oncology. J. Support. Oncol. 9(6), 208-209 (2011).
-
(2011)
J. Support. Oncol
, vol.9
, Issue.6
, pp. 208-209
-
-
Barnes, E.A.1
-
13
-
-
83455244321
-
Radiopharmaceuticals: When and how to use them to treat metastatic bone pain
-
Paes FM, Ernani V, Hosein P, Serafini AN. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J. Support. Oncol. 9(6), 197-205 (2011).
-
(2011)
J. Support. Oncol
, vol.9
, Issue.6
, pp. 197-205
-
-
Paes, F.M.1
Ernani, V.2
Hosein, P.3
Serafini, A.N.4
-
14
-
-
0042887586
-
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Tandomized phase ii trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate
-
Palmedo H, Manka-Waluch A, Albers P et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized Phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J. Clin. Oncol. 21(15), 2869-2875 (2003).
-
(2003)
J. Clin. Oncol
, vol.21
, Issue.15
, pp. 2869-2875
-
-
Palmedo, H.1
Manka-Waluch, A.2
Albers, P.3
-
15
-
-
0035798930
-
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase ii trial
-
Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised Phase II trial. Lancet 357(9253), 336-341 (2001).
-
(2001)
Lancet
, vol.357
, Issue.9253
, pp. 336-341
-
-
Tu, S.M.1
Millikan, R.E.2
Mengistu, B.3
-
16
-
-
34250368094
-
Clinical benefit of bone-targeted radiometabolic therapy with 153sm-edtmp combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
-
Ricci S, Boni G, Pastina I et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 34(7), 1023-1030 (2007).
-
(2007)
Eur. J. Nucl. Med. Mol. Imaging
, vol.34
, Issue.7
, pp. 1023-1030
-
-
Ricci, S.1
Boni, G.2
Pastina, I.3
-
17
-
-
84889252465
-
Safety and antitumor efficacy of (153)sm-edtmp and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer
-
Borso E, Boni G, Pastina I et al. Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer. Nucl. Med. Comm. 35(1), 88-94 (2014).
-
(2014)
Nucl. Med. Comm
, vol.35
, Issue.1
, pp. 88-94
-
-
Borso, E.1
Boni, G.2
Pastina, I.3
-
18
-
-
84921409492
-
The samdocet study: 153sm-edtmp and docetaxel versus docetaxel in taxane-naive patients with metastatic castration-refractory prostatecancer
-
Borso E, Mazzarri S, Boni G et al. The SAMDOCET study: 153Sm-EDTMP and docetaxel versus docetaxel in taxane-naive patients with metastatic castration-refractory prostatecancer. Eur. J. Nucl. Med. Mol. Imaging. 40, S497-S497 (2013).
-
(2013)
Eur. J. Nucl. Med. Mol. Imaging
, vol.40
, pp. S497-S497
-
-
Borso, E.1
Mazzarri, S.2
Boni, G.3
-
19
-
-
84901638475
-
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial
-
Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a Phase 3, double-blind, randomised trial. Lancet Oncol. 15(7), 738-746 (2014).
-
(2014)
Lancet Oncol
, vol.15
, Issue.7
, pp. 738-746
-
-
Sartor, O.1
Coleman, R.2
Nilsson, S.3
-
20
-
-
84887409151
-
Urological cancer: Alpha-emitting radium-223-additional choices, more unknowns
-
Higano C. Urological cancer: alpha-emitting radium-223-additional choices, more unknowns. Nat. Rev. Clin. Oncol. 10(11), 612-613 (2013).
-
(2013)
Nat. Rev. Clin. Oncol
, vol.10
, Issue.11
, pp. 612-613
-
-
Higano, C.1
-
21
-
-
84921343437
-
Alpha-emitter radium-223 in the management of solid tumors: Current status and future directions
-
Nilsson S. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions. Am. Soc. Clin. Oncol. Educ. Book 34l, e132-e139 (2014).
-
(2014)
Am. Soc. Clin. Oncol. Educ. Book
, vol.341
, pp. e132-e139
-
-
Nilsson, S.1
-
22
-
-
46949111791
-
Alpha-particles for targeted therapy
-
Sgouros G. Alpha-particles for targeted therapy. Adv. Drug Deliv. Rev. 60(12), 1402-1406 (2008).
-
(2008)
Adv. Drug Deliv. Rev
, vol.60
, Issue.12
, pp. 1402-1406
-
-
Sgouros, G.1
-
23
-
-
41949104346
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
-
Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148-1159 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.7
, pp. 1148-1159
-
-
Scher, H.I.1
Halabi, S.2
Tannock, I.3
-
24
-
-
84891835413
-
Visceral disease in castration-resistant prostate cancer
-
Pezaro CJ, Omlin A, Lorente D et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65(2), 270-273 (2014).
-
(2014)
Eur. Urol
, vol.65
, Issue.2
, pp. 270-273
-
-
Pezaro, C.J.1
Omlin, A.2
Lorente, D.3
-
25
-
-
84900503061
-
Safety of radium-223 dichloride (ra-223) with docetaxel (d) in patients with bone metastases from castration-resistant prostate cancer (crpc): A phase i prostate cancerclinical trials consortium study
-
Abstract 5021
-
Michael J, Morris HJH, Sweeney C et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a Phase I Prostate Cancerclinical Trials Consortium study. J. Clin. Oncol. 31(Suppl.), Abstract 5021 (2013).
-
(2013)
J. Clin. Oncol
, vol.31
-
-
Michael, J.1
Morris, H.J.H.2
Sweeney, C.3
-
31
-
-
84901852798
-
To treat or not to treat, that is the question: The role of bone-targeted therapy in metastatic prostate cancer
-
Higano CS. To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer. J. Clin. Oncol. 32(11), 1107-1111 (2014).
-
(2014)
J. Clin. Oncol
, vol.32
, Issue.11
, pp. 1107-1111
-
-
Higano, C.S.1
-
34
-
-
84907164048
-
Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: Samarium-153-edtmp and radium-223
-
Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and Radium-223. Adv. Exp. Med. Biol. 804, 291-304 (2014).
-
(2014)
Adv. Exp. Med. Biol
, vol.804
, pp. 291-304
-
-
Anderson, P.M.1
Subbiah, V.2
Rohren, E.3
|